STOCKHOLM, Sweden--(BUSINESS WIRE)--Meda (STO:MEDAA) and Ethypharm, a French development company, signed an exclusive 15-year agreement for an innovative combination product within the pain and inflammation therapy area (TA). The product consists of these well-recognised substances: omeprazole (proton pump inhibitor) and ketoprofen (NSAID). By using this novel product, patients can avoid serious gastrointestinal problems – a common NSAID side effect. Better improved compliance through once daily presentation.
